Viral hepatitis: global and regional situation and response

Dr Zsuzsanna Jakab
WHO Regional Director for Europe

3rd Hepatitis C Technical Advisory Group (TAG) Meeting
Tbilisi, Georgia, 30 November–1 December 2017
Global situation of hepatitis B virus (HBV) infections

Incidence:
• Chronic HBV infection in children under 5 reduced from 4.7% to 1.3% (immunization)

Prevalence:
• 257 million people living with HBV
• More than two thirds in African and Western Pacific regions
Global situation of hepatitis C virus (HCV) infections

Incidence:
• 1.75 million new infections per year (unsafe health care and injection drug use)

Prevalence:
• 71 million infected, all regions
Hepatitis B and C in the WHO European Region

HBV
- Estimated prevalence: 1.6%
- Estimated number of people living with infection: 15 million (2015)
- Estimated number of deaths: 56 000 (2015)

HCV
- Estimated prevalence: 1.5%
- Estimated number of people living with infection: 14 million (2015)
- Estimated number of deaths: 112 500 (2015)

Over 60% of those affected live in eastern European and central Asian countries.

Source: WHO Global hepatitis report, 2017
Global agenda: elimination of viral hepatitis as a public health threat by 2030

6–10 million infections (in 2015) to 900,000 infections (by 2030)

1.4 million deaths (in 2015) to less than 500,000 deaths (by 2030)
European action plan on viral hepatitis

Goal: eliminate viral hepatitis as a public health threat by 2030

Five strategic directions:

1. Information for focused action
2. Interventions for impact
3. Delivering for equity
4. Financing for sustainability
5. Innovation for acceleration

Universal health coverage: 3 dimensions
- the what
- the how
- the financing
Essential regional targets by 2020: on the way to the elimination of hepatitis

- **HCV - treatment**
- **HBV - treatment**
- **HCV - diagnosis**
- **HBV - diagnosis**
- **Harm reduction**
- **Injection safety**
- **Blood safety**
- **HBV - PMTCT**
- **HBV - vaccination**

2015 BASELINE vs 2020 TARGET

% coverage

* Measuring progress on prevention of mother-to-child transmission (PMTCT) is currently limited by lack of data on the screening coverage of pregnant women.

** Measuring progress on HBV treatment is currently limited by an absence of data on the proportion of people who are eligible.

Source: WHO Global hepatitis report, 2017
Countries stepping up to eliminate hepatitis

The number of countries with national hepatitis plans increased from 13 (in 2013) to 22 (in 2017) in our Region.

- Endorsed hepatitis action plans (22 countries)
- Developing hepatitis action plans (14 countries)
World Hepatitis Summit 2017
World Hepatitis Day 2017 in Tbilisi
Georgia’s HCV Elimination Programme – an example of best practices in the Region
THANK YOU!